Author: Aimil

For its persistent commitment towards healthcare based on Ayurveda, AIMIL pharmaceuticals won the Gold Award in the AYUSH brand of the year category at the India Health & Wellness Summit and Awards 2016. AIMIL’s product BGR-34 was awarded silver under the Health Innovations category at the same awards. Cutting through the shortlisted key industry players, AIMIL Pharmaceuticals bagged the award at 3rd edition of India Health & Wellness Summit and Awards held at Hotel Taj Palace, New Delhi.

On this occasion, Mr. K.K. Sharma, Managing Director, Aimil Pharmaceuticals (I) Ltd., shared, “Aimil Pharmaceuticals is highly committed to the accomplishment of its mission to reach out to the suffering patients in the country with the marvellous benefits of quality therapeutic answers to various difficult to address ailments and we feel honoured on having received these prestigious awards in recognition to our sincere concern towards national healthcare.”

Aimil, the recipient of 3 National Awards from Govt. of India, for manufacturing herbal medicines of outstanding quality, efforts in research & development and excellent entrepreneurship has been identified with promising answers to various challenging ailments. To name a few are – BGR-34 for effective management of diabetes, Lukoskin – to help patients fight the social stigma, leucoderma, Neeri KFT – for maintaining and improving kidney functions in cases of deteriorating once.

The importance of Ayurveda as a promising healthcare science is being recognised and appreciated not only in the country but also all over the globe. These awards further help spread the importance of Ayurveda, the knowledge of healthy life across the country.

The India Health and Wellness Summit and Awards honours the excellence in Health and alternative therapies to reward, salute and recognize companies and individuals with Business in India for excellence in their performance. The day long programme had deliberations from various eminent speakers on the issues of utmost importance in the present day scenario like air quality, nutritious food creation and distribution, making water sustainable for life and health and healthcare at large.

The programme was graced by Dr. Manmohan Singh, Economist and Former Prime Minister of India, Shri. J.P. Nadda, Union Minister of Health and family welfare, GOI and Dr. Harsh Vardhan, Minister of Science and technology, as well.

India, 2016: “Ayurvedic anti diabetic drug BGR-34 is scientifically tested and very effective in treating type 2 Diabetes,” said Shripad Naik, Union Minister of State, Ministry of AYUSH in Rajya Sabha. While answering the question raised on the efficacy of BGR-34 Naik shared that the medicine has been launched in the market after undergoing all the required scientific tests. He further added that the drug has been successful in improving the blood glucose levels of the diabetes patients and is available on all major chemist counters across the country.

BGR-34 has also got number one position in anti-diabetic ayurvedic product category in IMS Health ranking and made its position among the top six brands in the survey conducted for new launches in Indian pharmaceuticals market.

The anti-diabetic drug, BGR-34, has been in the market for about 9 months now, which is developed and validated for its efficacy and safety by the scientists of “National Botanical Research Institute(NBRI)” and “Central Institute of Medicinal and Aromatic Plants (CIMAP)”, the research units of “Council of Scientific and Industrial Research(CSIR)” and manufactured & marketed by Aimil Pharmaceuticals (I) Ltd.

Mr. K. K. Sharma, Managing director of AIMIL Pharmaceuticals, said “Mr. Naik’s statement on BGR-34’s efficacy will further enhance patients’ trust in the medicine. With a strong marketing distribution network spread all over the country, Aimil is strongly committed to carry forward the marvellous benefits of this novel research to the suffering masses all throughout the country and abroad thereby, helping them fight this ever challenging, fast increasing metabolic disorder known to be a silent killer, far more effectively and make them enjoy good quality healthy life.”

Number of post launch studies have been carried out on BGR-34 over the last one year, which have suggested if used in pre-diabetic or mild conditions as monotherapy the drug effectively managed blood glucose homeostasis. In case of chronic and severe instances, it could be used as an adjuvant therapy to synthetic anti-diabetics. BGR-34 is found o provide valuable hepatoprotective, nephroprotective and dislipdemic activities to the advantage of diabetic patients.

Click to read more